BioNTech SE (BNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yaron Werber ...

Jefferies analyst Akash Tewari maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $150.00.

Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz director, ...

BioNTech (NASDAQ:BNTX – Get Free Report) will be announcing its earnings results before the market opens on Monday, November ...

On Monday, BioNTech SE (NASDAQ:BNTX) reported third-quarter revenues of 1.244 billion euros (or $1.36 billion), up from 895.3 ...

We expect BioNTech SE BNTX to surpass expectations when it reports third-quarter 2024 results on Nov. 4, before the opening ...

Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...

Mount Yale Investment Advisors LLC acquired a new stake in shares of BioNTech SE (NASDAQ:BNTX – Free Report) in the third quarter, according to the company in its most recent 13F filing with the ...

Pfizer (PFE) stock gained after the company beat estimates with its Q3 2024 financials and raised its full-year guidance ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

MAINZ, Germany, October 21, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2024 on Monday, November 4, 2024.